Israel - English - Ministry of Health

kamada ltd, israel - albumin human - solution for infusion - albumin human 200 mg/ml - albumin - albumin - for restoration and maintenance of circulating blood volume where volume deficiency has been demontrated and use of a colloid such as albumin is appropriate. the choice of albumin rather than artificial colloid will depend on the clinical situation of the individual patient based on official recommendations.

Malta - English - Medicines Authority

baxalta innovations gmbh industriestrasse 67, 1221, vienna, austria - albumin, human - solution for infusion - albumin, human 200 g/l - blood substitutes and perfusion solutions

Malta - English - Medicines Authority

baxalta innovations gmbh industriestrasse 67, 1221, vienna, austria - albumin, human - solution for infusion - albumin, human 50 g/l - blood substitutes and perfusion solutions

Malta - English - Medicines Authority

baxalta innovations gmbh industriestrasse 67, 1221, vienna, austria - albumin, human - solution for infusion - albumin, human 200 g/l - blood substitutes and perfusion solutions

Kenya - English - Pharmacy and Poisons Board

human albumin 20% - infusion - human albumin 20% - albumin

United States - English - NLM (National Library of Medicine)

csl behring ag - albumin human (unii: zif514rvzr) (albumin human - unii:zif514rvzr) - albumin human 12.5 g in 50 ml - since the oncotic pressure of alburx® 25, albumin (human) 25% solution is about four times higher than that of normal human serum, it will expand the plasma volume if interstitial water is available for an inflow through the capillary walls. however, many patients suffering from an acute volume deficit also have some degree of interstitial dehydration. in the absence of hyperhydration, the treatment of an acute volume deficit with alburx® 25 should therefore include isotonic electrolyte solutions with an albumin:electrolyte ratio of 1:3 or 1:4. by contrast, chronic volume deficits have usually been at least partially compensated for by the renal retention of sodium and water with some degree of tissue edema, and in these circumstances a trial with alburx® 25 only is indicated. in any case, an anemia of clinically relevant magnitude requires specific treatment, and the metabolic needs of the patient with respect to fluid and electrolytes must be cared for. the common causes of hypoproteinemia are protein-ca

Ireland - English - HPRA (Health Products Regulatory Authority)

csl behring gmbh - human albumin solution - solution for infusion - 20, 200 gram(s)/litre - albumin

Israel - English - Ministry of Health

takeda israel ltd - albumin human - solution for infusion - albumin human 200 mg / 1 ml - albumin - restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated and use of a colloid is appropriate.

Israel - English - Ministry of Health

takeda israel ltd - albumin human - solution for infusion - albumin human 50 mg / 1 ml - albumin - restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated and use of a colloid is appropriate.

United States - English - NLM (National Library of Medicine)

grifols usa, llc - albumin human (unii: zif514rvzr) (albumin human - unii:zif514rvzr) - albumin human 2.5 g in 50 ml - emergency treatment of hypovolemic shock plasbumin-5 is iso-oncotic with normal plasma and on intravenous infusion will expand the circulating blood volume by an amount approximately equal to the volume infused. in conditions associated mainly with a volume deficit, albumin is best administered as a 5% solution (plasbumin-5); but where there is an oncotic deficit, albumin (human) 25%, usp (plasbumin® -25) may be preferred. this is also an important consideration where the treatment of the shock state has been delayed. if plasbumin-25 is used, appropriate additional crystalloid should be administered.(1) crystalloid solutions in volumes several times greater than that of plasbumin-5 may be effective in treating shock in younger individuals who have no preexisting illness at the time of the incident. older patients, especially those with preexisting debilitating conditions, or those in whom the shock is caused by a medical disorder, or where the state of shock has existed for some time before active therapy cou